Day 2 of 2: FDA Pharmacy Compounding Advisory Committee, which includes physicians who promote unproven peptides, allows 2 peptides (free base and acetate forms) of unproven peptides on the Agency's 503A bulk drugs compounding list while rejecting emideltide